Brought to you by 
Italfarmaco to sell Helsinn's anamorelin in Italy
29 Jan 2014
Executive Summary
Long-time partners Italfarmaco SPA (cardiovascular, oncology, and CNS therapeutics) and the Helsinn Group teamed up again, with Helsinn granting Italfarmaco exclusive rights to sell its cachexia therapy anamorelin in Italy.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Italfarmaco to sell Helsinn's anamorelin in Italy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice